First line Immunotherapy for Non-Small Cell Lung Cancer
Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first line treatments protocols. Multiple phase 3 studies have tested different medications targeting programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI AG
2020-11-01
|
| coleção: | Pharmaceuticals |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/1424-8247/13/11/373 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
